← Back to Analyst Consensus 
HCM Buy
HUTCHMED (China) Ltd
Current Price —
Implied Upside —
Analysts 28
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Jul 23, 2026 | Goldman Sachs | maintain | Neutral → Neutral | — | 54% |
| Jul 7, 2026 | B of A Securities | maintain | Buy → Buy | — | 53% |
| Mar 10, 2026 | B of A Securities | maintain | Buy → Buy | — | 53% |
| Sep 22, 2025 | Morgan Stanley | downgrade | Equal-Weight → Underweight | $13.75 | 54% |
| Jul 22, 2025 | B of A Securities | maintain | Buy → Buy | $28 | 53% |
| Aug 1, 2024 | Goldman Sachs | maintain | Neutral → Neutral | $19 | 54% |
| Nov 24, 2023 | Deutsche Bank | upgrade | Hold → Buy | $22.1 | 57% |
| Nov 10, 2023 | Goldman Sachs | maintain | Neutral → Neutral | $17 | 54% |
| Sep 5, 2023 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $50 | 50% |
| Jul 24, 2023 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $50 | 50% |
| Aug 9, 2022 | Goldman Sachs | maintain | — → Neutral | $16 | 54% |
| Aug 2, 2022 | Goldman Sachs | maintain | — → Neutral | $14 | 54% |
| Sep 22, 2021 | Goldman Sachs | downgrade | Buy → Neutral | $46 | 54% |
| Aug 3, 2021 | Jefferies | initiate | — → Buy | $52 | 52% |
| Mar 13, 2020 | Cantor Fitzgerald | initiate | — → Overweight | $0 | 50% |
| Feb 20, 2020 | Goldman Sachs | initiate | — → Buy | $38 | 54% |
| Nov 19, 2019 | CLSA | initiate | — → Buy | $0 | 50% |
| Mar 4, 2019 | Deutsche Bank | initiate | — → Buy | $0 | 57% |
| Oct 17, 2017 | Canaccord Genuity | maintain | — → Buy | $38 | 48% |
| Apr 11, 2016 | Stifel | initiate | — → Buy | $0 | 53% |
| Apr 11, 2016 | Canaccord Genuity | initiate | — → Buy | $20 | 48% |
| Apr 11, 2016 | B of A Securities | initiate | — → Buy | $0 | 53% |
Price Target Trend
Jun 11, 2026 Oct 26, 2026
EPS Estimates
0y —
+1q —
+1y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days